Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 19, 2011

Ambry Genetics to Provide Entire Roche NimbleGen Array Portfolio

  • Ambry Genetics has officially become a Certified Service Provider (CSP) for NimbleGen comparative genomic hybridization (CGH), chromatin immunoprecipiation-on-chip (ChIP-chip), DNA methylation, and gene expression. The firm, Roche NimbleGen’s first CSP in the U.S., is now certified on all Roche NimbleGen applications, the first CSP to attain this status.

    A CAP-accredited, CLIA-certified commercial clinical laboratory, Ambry Genetics will process customer samples for copy number variation, DNA methylation analysis, gene-expression analysis, and DNA-protein interactions and chromatin structure. The company will use the complete NimbleGen Dual- and Single-Color microarray workflow, which includes the high-resolution MS 200 Microarray Scanner.

    Ambry was initiated as a Roche NimbleGen CSP in the U.S. during September 2010. The company became a supplier of NimbleGen's SeqCap EZ Exome sequence-capture technology, giving it the ability to offer target-enrichment services coupled with next-generation sequencing services for genetic research.

    Earlier this month Ambry Genetics became the first authorized CSP in Ion Torrent's new service provider program. Ion Torrent develops a sequencing system using semiconductor technology.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »